Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 3
2008 5
2009 4
2010 21
2011 12
2012 26
2013 47
2014 58
2015 37
2016 57
2017 61
2018 59
2019 54
2020 50
2021 34
Text availability
Article attribute
Article type
Publication date

Search Results

458 results
Results by year
Filters applied: . Clear all
Page 1
Lorcaserin.
[No authors listed] [No authors listed] 2020 Jun 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Jun 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644141 Free Books & Documents. Review.
Lorcaserin is a selective serotonin agonist that was used as a weight loss agent. Lorcaserin was in clinical use for eight years when it was withdrawn because of concerns regarding an excess in cancer risk after long term use. ...
Lorcaserin is a selective serotonin agonist that was used as a weight loss agent. Lorcaserin was in clinical use for eight yea
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
Higgins GA, Fletcher PJ, Shanahan WR. Higgins GA, et al. Pharmacol Ther. 2020 Jan;205:107417. doi: 10.1016/j.pharmthera.2019.107417. Epub 2019 Oct 16. Pharmacol Ther. 2020. PMID: 31629010 Review.
The selective 5-HT2C receptor agonist lorcaserin, in conjunction with lifestyle modification, was approved by the FDA in 2012 for weight management. ...Potential clinically-relevant effects of lorcaserin have also been reported in models of pain and seizure-like act …
The selective 5-HT2C receptor agonist lorcaserin, in conjunction with lifestyle modification, was approved by the FDA in 2012 for wei …
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA–TIMI 61 Steering Committee and Investigators. Bohula EA, et al. N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26. N Engl J Med. 2018. PMID: 30145941 Free article. Clinical Trial.
BACKGROUND: Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined. METHODS: We randomly assigned 12 …
BACKGROUND: Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management …
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators. Bohula EA, et al. Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293771 Free article. Clinical Trial.
Lorcaserin resulted in a non-significant increase in the rate of achievement of normoglycaemia in patients with prediabetes (185 [92%] vs 151 [76%]; 120, 097-149; p=0093). ...In patients with diabetes at baseline, severe hypoglycaemia with serious complications was rare, b
Lorcaserin resulted in a non-significant increase in the rate of achievement of normoglycaemia in patients with prediabetes (185 [92%
Obesity: Pathophysiology and Management.
Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Gadde KM, et al. J Am Coll Cardiol. 2018 Jan 2;71(1):69-84. doi: 10.1016/j.jacc.2017.11.011. J Am Coll Cardiol. 2018. PMID: 29301630 Free PMC article. Review.
Lifestyle modification is recommended as the cornerstone of obesity management, but many patients do not achieve long-lasting benefits due to difficulty with adherence as well as physiological and neurohormonal adaptation of the body in response to weight loss. Fortunately, 5 dru …
Lifestyle modification is recommended as the cornerstone of obesity management, but many patients do not achieve long-lasting benefits due t …
Lorcaserin Departs, Leaving More Questions than Answers.
Kumar R, Ryan D. Kumar R, et al. Obesity (Silver Spring). 2020 Jul;28(7):1167. doi: 10.1002/oby.22789. Epub 2020 Apr 22. Obesity (Silver Spring). 2020. PMID: 32320522 No abstract available.
Evaluation of lorcaserin for the treatment of obesity.
Berlie HD, Hurren KM. Berlie HD, et al. Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1053-9. doi: 10.1517/17425255.2013.798643. Epub 2013 Jun 26. Expert Opin Drug Metab Toxicol. 2013. PMID: 23802690 Review.
AREAS COVERED: The authors review the pharmacology and clinical efficacy as well as the safety and tolerability of lorcaserin. This was achieved through a PubMed search (1960 - present) on lorcaserin to generate the key literature in the area. ...Cardiovascular outc …
AREAS COVERED: The authors review the pharmacology and clinical efficacy as well as the safety and tolerability of lorcaserin. This w …
Management of obesity.
Bray GA, Frühbeck G, Ryan DH, Wilding JP. Bray GA, et al. Lancet. 2016 May 7;387(10031):1947-56. doi: 10.1016/S0140-6736(16)00271-3. Epub 2016 Feb 10. Lancet. 2016. PMID: 26868660 Free article. Review.
Medications approved in the USA or European Union are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and phentermine/topiramate are also available. Surgical management (gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce …
Medications approved in the USA or European Union are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and phe …
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Khera R, et al. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602. JAMA. 2016. PMID: 27299618 Free PMC article. Review.
STUDY SELECTION: Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approved long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 ye …
STUDY SELECTION: Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approve …
458 results